[10 May 2013]

Products Affected - Description

Hydromorphone Injection, Hospira

2 mg/mL, 1 mL vials (NDC 00409-3365-01)

Reason for the Shortage

Hospira has hydromorphone injection on shortage due to manufacturing delays.

Available Products

Hydromorphone injection, Akorn
10 mg/mL, 1 mL ampules (NDC 17478-0540-01)
10 mg/mL, 5 mL ampules (NDC 17478-0540-05)
10 mg/mL, 50 mL vials (NDC 17478-0540-50)

 

Hydromorphone injection, Hospira

1 mg/mL, 0.5 mL iSecure syringes (NDC 00409-1283-05)

1 mg/mL, 1 mL Carpuject syringes (NDC 00409-1283-31)

1 mg/mL, 1 mL iSecure syringes (NDC 00409-1283-10)
1 mg/mL, 1 mL ampules (NDC 00409-2552-01)
2 mg/mL, 1 mL Carpuject syringes (NDC 00409-1312-30)

2 mg/mL, 1 mL iSecure syringes (NDC 00409-1312-10)

2 mg/mL, 1 mL ampules (NDC 00409-3356-01)

4 mg/mL, 1 mL ampules (NDC 00409-2540-01)
4 mg/mL, 1 mL Carpuject syringes (NDC 00409-1304-31)

10 mg/mL, 1 mL vials (NDC 00409-2634-01)

10 mg/mL, 5 mL vials (NDC 00409-2634-05)

10 mg/mL, 50 mL vials (NDC 00409-2634-50)

Hydromorphone injection, Teva
10 mg/mL, 1 mL vials (NDC 00703-0110-03)
10 mg/mL, 5 mL vials (NDC 00703-0113-03)
10 mg/mL, 50 mL vials (NDC 00703-0118-01)

 

Hydromorphone Injection, West-Ward
2 mg/mL, 1 mL vials (NDC 00641-0121-25)

2 mg/mL, 20 mL multi-dose vials (NDC 00641-2341-41)

 

Dilaudid injection, Purdue
1 mg/mL, 1 mL ampules, package of 10 (NDC 59011-0441-10)

2 mg/mL, 1 mL ampules, package of 10 (NDC 59011-0442-10)
2 mg/mL, 1 mL ampules, package of 25 (NDC 59011-0442-25)
4 mg/mL, 1 mL ampules, package of 10 (NDC 59011-0444-10)

 

Dilaudid-HP injection, Purdue
250 mg vial, powder for injection (NDC 59011-0446-25)
10 mg/mL, 1 mL ampules (NDC 59011-0445-01)
10 mg/mL, 5 mL ampules (NDC 59011-0445-05)
10 mg/mL, 50 mL vials (NDC 59011-0445-50)

Estimated Resupply Dates

Hospira has hydromorphone 2 mg/mL 1 mL vials available in limited quantities and the company cannot estimate when additional supplies may become available.

Related Shortages

• Oxycodone Immediate Release Solution— Resolved
• Oxymorphone Hydrochloride
• Paregoric Liquid— Resolved

Updated

May 10, 2013; March 27, 2013; March 4, 2013; February 14, 2013; January 25, 2013; December 20, 2012; December 4, 2012; November 27, 2012; November 16, 2012; October 31, 2012; October 11, 2012; September 27, 2012; September 12, 2012; August 17, 2012; July 27, 2012; July 10, 2012; June 22, 2012; June 21, 2012; May 17, 2012; April 13, 2012; April 5, 2012; March 12, 2012; March 2, 2012; February 16, 2012; February 9, 2012; January 24, 2012; January 11, 2012; December 29, 2011; December 21, 2011; December 7, 2011; November 23, 2011; October 31, 2011, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins